Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 116 points (0.8%) at 15,038 as of Monday, Sept. 9, 2013, 12:44 PM ET. The NYSE advances/declines ratio sits at 2,262 issues advancing vs. 646 declining with 106 unchanged. The Drugs industry currently sits up 1.4% versus the S&P 500, which is up 0.7%. Top gainers within the industry include Isis Pharmaceuticals ( ISIS), up 11.5%, Incyte ( INCY), up 5.5% and Novo Nordisk A/S ( NVO), up 1.5%. TheStreet would like to highlight 5 stocks pushing the industry higher today: 5. Biomarin Pharmaceutical ( BMRN) is one of the companies pushing the Drugs industry higher today. As of noon trading, Biomarin Pharmaceutical is up $1.84 (2.5%) to $74.54 on heavy volume. Thus far, 1.2 million shares of Biomarin Pharmaceutical exchanged hands as compared to its average daily volume of 1.0 million shares. The stock has ranged in price between $72.49-$74.54 after having opened the day at $72.50 as compared to the previous trading day's close of $72.70. BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. Biomarin Pharmaceutical has a market cap of $9.9 billion and is part of the health care sector. Shares are up 47.8% year to date as of the close of trading on Friday. Currently there are 11 analysts that rate Biomarin Pharmaceutical a buy, no analysts rate it a sell, and 3 rate it a hold. TheStreet Ratings rates Biomarin Pharmaceutical as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including weak operating cash flow and feeble growth in the company's earnings per share. Get the full Biomarin Pharmaceutical Ratings Report now. 3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.